Related Experiment Video

Updated: Jun 10, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Antiangiogenic strategies in breast cancer management

Monica Giovannini1, Daniela Aldrighetti, Patrizia Zucchinelli

  • 1Medical Oncology Unit, Oncology Dept, San Raffaele Scientific Institute-University Hospital, Milan, Italy. giovannini.monica@hsr.it

Critical Reviews in Oncology/Hematology
|August 13, 2010
PubMed

Insights

Angiogenesis is crucial for tumor growth, making antiangiogenic therapies a key focus in breast cancer treatment. This review covers current data and investigates major antiangiogenic strategies targeting vascular endothelial growth factor (VEGF).

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is essential for tumor growth and survival.
  • Targeting angiogenesis presents a promising therapeutic strategy for various solid tumors, including breast cancer.

Purpose of the Study:

  • To review current data supporting the role of angiogenesis in breast cancer.
  • To provide a comprehensive overview of antiangiogenic therapies investigated for breast cancer.

Main Methods:

  • Literature review of studies on angiogenesis in breast cancer.
  • Analysis of clinical data for antiangiogenic agents targeting vascular endothelial growth factor (VEGF).

Main Results:

  • Vascular endothelial growth factor (VEGF) is a primary target for antiangiogenic therapies.
  • Therapies include monoclonal antibodies and tyrosine kinase inhibitors against VEGF(R).
  • Other agents like hormonal therapy and chemotherapy also exhibit antiangiogenic activity.

Conclusions:

  • Antiangiogenic therapies targeting VEGF are a significant area of research in breast cancer.
  • A range of therapeutic approaches demonstrate antiangiogenic potential in breast cancer treatment.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...